ASCO 2026 wasn’t just about new data—it highlighted where oncology is headed next. From breakthrough in vivo CAR-T results and RAS-targeted therapies to the growing influence of Chinese biotech on the global stage, this year’s meeting showcased the evolving future of cancer care. Listen to the recap: https://www.fiercepharma.com/pharma/behind-headlines-asco-2026
More Tips From The Bandish Group
Is Flexible Work Flexible Enough for a 100-Year Life?
◆
As careers become longer, employers may need to rethink traditional approaches to career advancement, retirement, and workplace flexibility. In her…
#452: Don’t Turn Your Job Description Into a Wish List
◆
Requiring too many qualifications can unnecessarily shrink your candidate pool. Separate your must-have qualifications from the skills that can be…